ASCO NEWS!
Anti-PD1, a misnomer, yes I believe!
isn't it longer true that if you block programmed cell death, you worsen a cancer?
well don't believe what make sense, "Antibody mediated blockade of the programmed cell death protein-1 and its ligand PD-L1 resulted in a potent and durable tumor regression and prolonged stabilization of disease in patients with solid tumors"...Nivolumad in combination with Ipilumumab yielded a 40% response rate in advanced Melanoma, this is impressive!  "The Synergie between Anti-PD-1 and an Anti-CTLA-4 has been confirmed".

*pomalidomide has been approved for Multiple Myeloma after failure of 2 regimens which contained Velcade and Revlimid. Officially approval was not based on increased survival! 

*Now enroling Trial "A Phase 3 trial for Newly diagnosed EGFRvIII-positive Glioblastoma :Rindopepimut and Temodar Vs Blinded KLH control and Temodar" NCT01480479